Transcriptomics

Dataset Information

0

Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway


ABSTRACT: Cholestasis is characterized by hepatic accumulation of cytotoxic bile acids (BAs), which often subsequentlyleads to liver injury, inflammation, fibrosis, and ultimately liver cirrhosis. Fibroblast growth factor 21 (FGF21) is a liver secreted hormone with pleiotropic effects on the homeostasis of glucose, lipid, and energy metabolism. However, whether hepatic FGF21 plays a role in cholestatic liver injury remains elusive. We found that serum and hepatic FGF21 levels were significantly increased in response to cholestatic liver injury. Hepatocyte-specific deletion of Fgf21 exacerbated hepatic accumulation of BAs, further accentuating liver injury. Consistently, administration of rFGF21 ameliorated cholestatic liver injury in α-naphthylisothiocyanate (ANIT)-treated and Mdr2 deficiency mice. Mechanically, FGF21 activated a hepatic FGFR4-JNK signaling pathway to decrease Cyp7a1 expression, thereby reducing hepatic BAs pool. Our study demonstrates that hepatic FGF21 functions as an adaptive stress-responsive signal to downregulate BA biosynthesis, thereby ameliorating cholestatic liver injury, and FGF21 analogs may represent a candidate therapy for cholestatic liver diseases.

ORGANISM(S): Mus musculus

PROVIDER: GSE240733 | GEO | 2023/08/19

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2015-08-26 | E-GEOD-72387 | biostudies-arrayexpress
2015-08-26 | GSE72387 | GEO
2018-02-09 | GSE110391 | GEO
2019-11-19 | GSE139075 | GEO
2024-08-29 | GSE183687 | GEO
| PRJNA1005176 | ENA
2020-12-16 | PXD023155 |
2020-06-30 | GSE144726 | GEO
2015-01-15 | E-GEOD-64970 | biostudies-arrayexpress
2022-03-10 | PXD025268 | Pride